Key facts
- Real And Best’s last known valuation is $58.7M (Feb 2021).
- It has raised $30.0M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Morningside Group, Orinno Capital, Sichuan Venture Capital, Beijing Delian Yuntong Investment Management Company, Chengdu New Economy Venture Capital — 15 tracked in total.
- Status: Privately Held (backing).
Investors
15+- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Real And Best
- ·The full record, as it builds
Funding rounds
No funding rounds for Real And Best are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Real And Best
Developer and researcher of biomedical drugs designed to edit and repair the expression of genes causing disease. The company's drug pipeline includes cutting-edge genomics drugs (rAAV gene drugs) for the repair and therapy of chronic diseases, providing innovative gene-based pharmaceutical solutions for medical practitioners and research institutions to treat haemophilia and other neurological and genetic conditions.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2018
- Ownership
- Privately Held (backing)
Real And Best doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Real And Best shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Real And Best in its N-PORT filings yet. We sweep new filings monthly.